[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indocyanine-green\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indocyanine-green":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,48,74,103,133,165,193,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643524","phase-4-comparing-intraoperative-indocyanine-green-fluorescence-imaging-with-standard-clinical-assessment-for-flap-perfusion-in-head-and-neck-reconstruction-vision-trial-100643524",false,"NCT07635420","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction: A Randomised Controlled Trial (VISION Trial)","VISION","Inclusion Criteria:\n\n* Age ≥18 years at the time of inclusion\n* Scheduled to undergo microvascular free flap reconstruction as part of oncologic, trauma, or benign surgery in the head and neck area\n* Ability to understand study information and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to indocyanine green or iodine\n* Severe hepatic or renal impairment\n* Confirmed or suspected pregnancy\n* Breastfeeding","ALL","18 Years",{"count":20,"type":21},244,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a prospective multicentre randomised controlled trial evaluating whether intraoperative indocyanine green (ICG) fluorescence angiography improves outcomes in head and neck free flap reconstruction compared with standard clinical assessment of flap perfusion. Adult patients undergoing microvascular free flap reconstruction for oncologic, trauma, or benign head and neck defects will be randomised to either intraoperative ICG angiography or conventional clinical perfusion assessment. The primary outcome is partial flap loss requiring intervention within 30 days after surgery. Secondary outcomes include total flap loss, flap-related re-exploration, flap salvage, and postoperative complications.",[27,28,29,30,31,32,33,34],"Head and Neck Cancer (H&N)","Free Tissue Flaps","Free Flap","Free Flap Evaluation","Indocyanine Green","Indocyanine Green (ICG)","Microsurgery","Randomised Controlled Trial","NOT_YET_RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":21},"2026-10-01",{"date":43,"type":21},"2029-08-01",{"name":45,"class":46},"Region Skane","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100616255","phase-3-the-value-of-indocyanine-green-guided-near-infrared-fluorescence-technology-in-tracing-sentinel-lymph-nodes-during-esophagectomy-100616255","NCT07303231","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age and gender: 18-75 years old, male and female unlimited;\n2. Preoperative biopsy was pathologically diagnosed as esophageal squamous cell carcinoma;\n3. Preoperative combination with neoadjuvant chemoradiotherapy;\n4. Surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis;\n5. Heart, lung, liver and kidney functions can tolerate operation;\n6. Patients and their family members can understand and are willing to participate in this clinical study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Allergic to ICG or iodine;\n2. Patients with a history of chest surgery or thoracic lymph node dissection;\n3. Patients needing emergency surgery;\n4. Patients whose tumors involve neighboring organs and need to be removed by combining organs;\n5. Patients with tumor recurrence or distant metastasis;\n6. Patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included;\n7. A history of serious mental illness;\n8. Pregnant or lactating women;\n9. Patients with other conditions considered by the researcher should not participate in the study.","75 Years",{"count":57,"type":21},144,[59],"PHASE3","Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies. The investigators plan to conduct a multicenter, prospective cohort study to evaluate the effectiveness of indocyanine green (ICG)-guided near-infrared imaging in tracing sentinel lymph node during esophageal squamous cell carcinoma (ESCC) surgery, compared with the gold standard of complete lymph node dissection (CLND), in detecting metastatic disease. This study aims to address the following core questions:\n\n1. In ESCC patients undergoing surgery, can sentinel lymph node biopsy reduce unnecessary lymph node dissection?\n2. In ESCC patients undergoing surgery, can reducing lymph node dissection decrease postoperative complications such as chylothorax and weakened immunity? During the study, ICG will be injected around the tumor under intraoperative gastroscopy guidance, followed by tracking of fluorescent lymph nodes using a thoracoscopic near-infrared camera. Professional thoracic surgeons will group and mark these lymph nodes for intraoperative frozen pathology. Subsequent CLND and routine postoperative pathology will be performed. This study will collect patients' clinical information, ICG imaging results, pathological examination results, and other data for statistical analysis to assess the sensitivity and negative predictive value (NPV) of the ICG imaging system. If the study results support the effectiveness of the ICG imaging system, it has the potential to become an important tool for sentinel lymph node localization and biopsy in future ESCC surgeries, helping to reduce unnecessary lymph node resection and improve surgical efficiency and safety.\n\nParticipants will:\n\n1. Undergo minimally invasive ESCC surgery within 2 weeks of enrollment, including the 14th day.\n2. Receive ICG injection around the tumor under intraoperative gastroscopy guidance during surgery.\n3. Have perioperative, postoperative pathology, and complication information recorded.\n4. Undergo standardized follow-up after surgery.",[62,63,64,31],"Esophageal Cancer","Sentinel Lymph Node","Lymphadenectomy","2025-12-11",{"date":67,"type":39},"2025-12-24",{"date":69,"type":21},"2026-01-01",{"date":71,"type":21},"2028-02-01",{"name":73,"class":46},"Fujian Medical University Union Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100606862","the-use-of-indocyanine-green-fluorescence-icg-during-laparoscopic-heller--dor-100606862","NCT07181070","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor: a Prospective Study","Inclusion Criteria:\n\n* patients with achalasia of type I and II\n* patients undergoing laparoscopic Heller-Dor\n* patients older than 18 years\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age;\n* Uncooperative patients and\u002For patients unable to provide informed consent\n* ASA ≥4\n* BMI ≥30\n* Patients previously treated with other endoscopic\u002Fsurgical procedures (botulinum toxin injections, dilation, POEM, myotomy)\n* Patients with achalasia type III\n* Patients with megaesophagus\n* Allergy to dyes or contrast agents included in the protocol (e.g., indocyanine green, barium, gastrografin)",{"count":82,"type":21},70,"1 Year","OBSERVATIONAL","The aim this prospective observational study is to evaluate the role of Indocyanine Green Fluorescence (ICG) in patients with achalasia underwent to Heller-Dor laparoscopic. The main gol are:\n\n* If with use of ICG iatrogenic mucosal leaks can be identified and, if necessary, improve the myotomy.\n* Assess the need for postoperative radiographic control using esophagogastric radiography with gastrografin.\n* Compare clinical characteristics, perioperative outcomes, and 12-month postoperative follow-up between the two populations.",[87,88,32,31],"Achalasia, Esophageal","Achalasia",[90,91,92],"achalasia","Laparoscopic Heller-Dor","Indocyanine Green Fluorescence","RECRUITING","2025-09-18",{"date":96,"type":39},"2025-09-23",{"date":98,"type":39},"2022-11-01",{"date":100,"type":21},"2026-10-31",{"name":102,"class":46},"Federico II University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100582797","phase-1-multi-center-study-on-ccell-in-vivos-clinical-efficacy-for-intraoperative-brain-tumor-diagnosis-100582797","NCT06867978","Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.","A Prospective, Multi-Center, Assessor-Blinded Study on the Clinical Efficacy of CCeLL-In Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis.","PRECISION","Inclusion Criteria:\n\n* Male or female patients aged 18 years or older\n* Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection\n* Patients who understand and have signed the informed consent form\n\nThe specimens used in this study must meet all of the following criteria:\n\n* Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria\n* Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients\n\nExclusion Criteria:\n\n* Patients undergoing multiple surgeries\n* Patients with bacterial or viral infections\n* Patients who develop allergic reactions to the investigational medical device\n* Patients with a history of allergy to Indocyanine Green (ICG)\n* Patients with iodine hypersensitivity\n* Patients taking choleretic agents or rifampicin\n\nSpecimens meeting any of the following criteria will be excluded from this clinical trial:\n\n\\- Specimens with unclear tumor presence or carcinoma diagnosis results based on the reference standard permanent section analysis",{"count":112,"type":21},100,[114],"PHASE1","The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, which is then read and analyzed by trained-professional for intraoperative diagnosis. The comparison will be held by the device with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.",[117,31,118],"Frozen Sections","Brain Tumor",[120,121,122],"Diagnostic Imaging","intraoperative","confocal laser endomicroscopy","2025-03-04",{"date":125,"type":39},"2025-03-10",{"date":127,"type":21},"2025-06-01",{"date":129,"type":21},"2026-12-31",{"name":131,"class":132},"VPIX Medical","INDUSTRY",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":84,"phases":4,"briefSummary":143,"conditions":144,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100570559","augur-ai---indocyanine-green-fluorescence-angiography-representer-100570559","NCT06708819","AUGUR-AI - Indocyanine Green Fluorescence Angiography Representer","AUGUR-AI","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Aged 18 years or above.\n* Colorectal disease requiring segmental resection with anastomosis.\n* Participant has clinically acceptable laboratory results, including liver function tests.\n* In the Investigator's opinion, is able and willing to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\nThe participant may not enter the study if ANY of the following apply:\n\n* Participant who is pregnant, lactating or planning pregnancy during the course of the study.\n* Significant renal or hepatic impairment.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Allergy to intravenous contrast agent or indocyanine green.\n* Concurrent use of anticonvulsants, bisulphite containing drugs, methadone and nitrofurantoin.",{"count":141,"type":21},300,"90 Days","Surgery can effectively treat colorectal cancer, but it is a complex procedure with risks and complications. Surgeons often rely on cameras to visually guide their instruments during operations, especially in minimally invasive (\"keyhole\") and endoscopic procedures. The camera is connected to a computer and generates the internal scene onto a display screen, which the surgeon looks at throughout the procedure, helping them make informed decisions throughout the operation. Fluorescence-guided surgery uses a particular type of camera that can detect images in both normal light and in the near-infrared range. To work, it needs the administration of an agent called indocyanine green to a patient and then the camera can see if the agent is in the tissue of interest to the operation at the time of the surgery. In this way, decisions regarding blood supply (\"perfusion\") can be helped, especially related to safety in joining together portions of tissue after removal of disease. The equipment and agent are approved for use in this way and have very good safety profiles. Many international studies have already demonstrated that the use of fluorescence-guided surgery is associated with lower rates of leaks when disease bowel segments are removed, and the healthy ends are joined back together.\n\nPrevious work we have done has shown that sophisticated computing methods can learn to interpret the fluorescence patterns to a similar standard as a surgeon who is very experienced in fluorescence-guided surgery.\n\nIn this study, we aim to assess whether the computer system we have developed work in real-time, in theatre to provide a reliable interpretation of the fluorescence pattern, that would match how an expert would interpret the same pattern. The system's analysis will not impact on the operation; instead, video images will be recorded, processed and analysed by our computer system. The results of the interpretation will not be shown to the operating surgeon during the procedure to avoid any impact on decision-making.",[145,146,147,148,31,149,150],"Colorectal Surgery","Colorectal Resection","Anastomosis, Surgical","Fluorescence Guided Surgery","Perfusion Imaging","Anastomotic Leaks",[152,31,153,154,155],"Fluorescence","Artificial Intelligence","Bowel Transection","Anastomotic Leak","2024-11-26",{"date":158,"type":39},"2024-11-27",{"date":160,"type":21},"2025-01",{"date":162,"type":21},"2026-01",{"name":164,"class":46},"Mater Misericordiae University Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100539372","atomized-inhalation-icg-for-treatment-of-congenital-lung-malformations-100539372","NCT06302985","Atomized Inhalation ICG for Treatment of Congenital Lung Malformations","Application of Atomized Inhalation ICG in Thoracoscopic Surgery for Pulmonary Sequestration in Children: a Multicentre Prospective Study","Inclusion Criteria:\n\n* children with congenital lung malformations diagnosed by CT or MRI scan\n\nExclusion Criteria:\n\n* 1\\. ages \\\u003C3 months and \\>14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection","3 Months","14 Years",{"count":175,"type":21},50,[177],"NA","To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children.",[180,181,31,182,183],"Pulmonary Sequestration","Congenital Pulmonary Airway Malformation","Thoracoscopic Surgery","Children","2024-10-13",{"date":186,"type":39},"2024-10-16",{"date":188,"type":39},"2024-03-01",{"date":190,"type":21},"2050-12-31",{"name":192,"class":46},"Jiexiong Feng",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":47},"100554640","icg-angiogram-as-a-predictor-of-postoperative-visual-function-after-eea-surgery-100554640","NCT06501716","ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery","I See G: Superior Hypophyseal Artery Intraoperative Indocyanine Green Angiogram as a Predictor of Postoperative Visual Function After Endoscopic Endonasal Surgery","Inclusion Criteria:\n\n* The study will enroll adult (18 y.o. and older) participants undergoing endonasal endoscopic surgery for suprasellar tumors including meningiomas, craniopharyngiomas and pituitary adenomas.\n\nExclusion Criteria:\n\n* Underage patients (younger than 18 y.o).",{"count":201,"type":21},40,"Endonasal endoscopic approaches are an established treatment for suprasellar lesions compromising the optic nerves (ON). Surgery often involves dissecting tumors from the optic nerves and its blood supply, which can result in nerve damage and visual loss after surgery. To date, there are no reliable methods to monitor the optic nerve function during surgery and thus, post-surgical visual outcomes is unknown until the patients are fully awake after surgery for a visual exam. This delay in diagnosis prevents early therapeutic measures and can result in further harm to the ON. We have recently recognized that when ICG is routinely injected during these cases to check for patency of the big arteries the sub millimetric superior hypophyseal arteries supplying (SHA) the ON are also visible and that lack of visualization of these vessels is associated with worse visual deficits after surgery. Thus, ICG may be a tool to intraoperative predict visual outcomes after endonasal approach for suprasellar lesions and fill the nondiagnostic gap. This study will assess whether endoscopic ICG angiography before and after resection of suprasellar lesions can predict post-operative visual deficits. Successful completion will provide surgeons a novel tool to assess visual function during surgery. The ICG endoscopic angiograms suggested in this study are noninvasive and currently routinely performed at the end of surgery to check for patency of big brain arteries.",[31,204],"Skull Base Neoplasms","2024-07-18",{"date":207,"type":39},"2024-07-22",{"date":209,"type":21},"2024-07",{"date":211,"type":21},"2025-12",{"name":213,"class":46},"University of California, San Francisco",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":47},"100437223","phase-2-indocyanine-green-tracer-using-in-laparoscopic-distal-gastrectomy-for-early-gastric-cancer-100437223","NCT04973475","Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer","Prospective Clinical Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy With Lymph Node Dissection for Early Gastric Cancer","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy\n3. Clinical stage tumor T1 (cT1), N0\u002F+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition. Preoperative staging was made by conducting mandatory computed tomography (CT) scans and an optional endoscopic ultrasound\n4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations\n5. Tumor located in the lower third of the stomach, expected to receive radical distal gastrectomy\n6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)\n7. American Society of Anesthesiology score (ASA) class I, II, or III\n8. Written informed consent\n\nExclusion Criteria:\n\n1. Women during pregnancy or breast-feeding\n2. Severe mental disorder\n3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)\n4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection\n5. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging\n6. History of other malignant disease within past five years\n7. History of previous neoadjuvant chemotherapy or radiotherapy\n8. History of unstable angina or myocardial infarction within past six months\n9. History of cerebrovascular accident within past six months\n10. History of continuous systematic administration of corticosteroids within one month\n11. Requirement of simultaneous surgery for other disease\n12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer\n13. Forced expiratory volume in 1 second (FEV1)\\\u003C50% of predicted values\n14. Rejection of laparoscopic resection\n15. Preoperatively confirmed tumors invading the dentate line or duodenum\n16. History of allergy to iodine agents\n17. Tumor located in the upper third of the stomach, expected to receive radical total gastrectomy",{"count":222,"type":21},180,[224],"PHASE2","This study aims to explore the value of indocyanine green (ICG) in laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer.The patients with early gastric adenocarcinoma (cT1, N-\u002F+, M0) will be studied.",[227,31,228],"Early Gastric Cancer","Lymph Node Dissection",[230,231,232,228],"Stomach Neoplasms","Indocyanine Green Tracer","Laparoscopic Distal Gastrectomy","2021-07-13",{"date":235,"type":39},"2021-07-22",{"date":237,"type":21},"2021-07",{"date":239,"type":21},"2026-07",{"name":241,"class":46},"Fujian Medical University"]